Q1 EPS Forecast for Monopar Therapeutics Cut by Analyst

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst S. Lee now expects that the company will earn ($0.44) per share for the quarter, down from their previous forecast of ($0.35). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.89) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at $0.72 EPS and FY2028 earnings at $2.08 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87).

Several other equities research analysts have also recently weighed in on MNPR. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $30.00 on Thursday. The company’s fifty day moving average is $38.29 and its two-hundred day moving average is $24.88. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30. The firm has a market capitalization of $183.39 million, a price-to-earnings ratio of -15.23 and a beta of 1.01.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $45,000. Geode Capital Management LLC grew its position in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Insider Transactions at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares of the company’s stock, valued at $28,778,925. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.